LivaNova study size potential could provide revenue upside: Piper Jaffray

Piper Jaffray analyst Matt O’Brien noted that details of LivaNova’s RECOVER trial were posted on clinicaltrials.gov, stating that much of the study appears in-line with prior expectations though the study can enroll as many as 1,000 patients, which is up from a previously guided 500 patients. Management still believe that 500 will be the right figure in the RCT portion, but the larger potential size of the study may provide some revenue upside, O’Brien said. The analyst, who noted that the study will begin enrolling at the end of July and has a primary completion date of August, 2022, keeps an Overweight rating on LivaNova shares.

https://thefly.com/landingPageNews.php?id=2883879